Decapeptide-12 is a synthetic peptide (with sequence Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr) known under the trade name Lumixyl™ that acts as a tyrosinase inhibitor, the enzyme responsible for the production of melanin in the skin. In fact, in vitro studies show that Decapeptide-12 is 5.5 times more effective than hydroquinone at equivalent doses in the moderation of melanin.
Developed by dermatological researchers at Stanford University, Decapeptide-12 smart and targeted peptide has been shown by in vitro studies to promote a reduction in the expression of melanin, yielding a blended, more even complexion in all skin types. It is an effective approach for long-term hyperpigmentation management suitable for all skin types.
In addition, Decapeptide-12 allows avoid hypopigmentation a common adverse effect in hyperpigmentation and dark spot treatment. It is effective even in minimal quantities and starts work at concentrations as low as 0.01%.
Preliminary clinical study results are being evaluated in large confirmatory trials and demonstrate the peptide's ability to yield visible results in improving the appearance of melasma. Study participants included persons who had previously been unsuccessful following six-month terms using a hydroquinone, retinol, and steroid regimen but reported visible improvements with Decapeptide-12 in as little as 8 weeks with a 50% improvement after 16 weeks.Related ingredients
